APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaginosis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vaginosis Drug Industry Growth and Trends Forecast to 2032

Report ID 174044930122 December 2025118 pages

Choose your research edition.

Industry ResearchVaginosis Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaginosis Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Vaginosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaginosis Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaginosis Drug Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Vaginosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vaginosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vaginosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaginosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vaginosis Drug include Yunnan Baiyao, Abbott, Xiuzheng, Teva, Sanofi, Pfizer, Bayer, West-Ward and Starpharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vaginosis Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vaginosis Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vaginosis Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vaginosis Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vaginosis Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vaginosis Drug Market by Company

Yunnan Baiyao

Abbott

Xiuzheng

Teva

Sanofi

Pfizer

Bayer

West-Ward

Starpharma

Piramal

Perrigo

Novel

Mission

HPGC

Galderma

Edenvridge

Alkem

Vaginosis Drug Segment by Type

Rx

OTC

Vaginosis Drug Segment by Application

Hospital

Pharmacy

Other

Vaginosis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaginosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaginosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaginosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vaginosis Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vaginosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Rx Table 2. Major Company of OTC Table 3. Global Vaginosis Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Vaginosis Drug Sales by Type (2021-2026) & (k units) Table 5. Global Vaginosis Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global Vaginosis Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global Vaginosis Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global Vaginosis Drug Price by Type (2021-2026) & (US$/unit) Table 9. Global Vaginosis Drug Sales by Type (2027-2032) & (k units) Table 10. Global Vaginosis Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global Vaginosis Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global Vaginosis Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global Vaginosis Drug Price by Type (2027-2032) & (US$/unit) Table 14. North America Vaginosis Drug Sales by Type (2021-2026) & (k units) Table 15. North America Vaginosis Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Vaginosis Drug Sales by Type (2021-2026) & (k units) Table 17. Europe Vaginosis Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Vaginosis Drug Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Vaginosis Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Vaginosis Drug Sales by Type (2021-2026) & (k units) Table 21. Latin America Vaginosis Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Vaginosis Drug Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Vaginosis Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Vaginosis Drug Industry Trends Table 25. Vaginosis Drug Industry Drivers Table 26. Vaginosis Drug Industry Opportunities and Challenges Table 27. Vaginosis Drug Industry Restraints Table 28. Global Vaginosis Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Vaginosis Drug Revenue Market Share by Company (2021-2026) Table 30. Global Vaginosis Drug Sales by Company (2021-2026) & (k units) Table 31. Global Vaginosis Drug Sales Share by Company (2021-2026) Table 32. Global Vaginosis Drug Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Vaginosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Vaginosis Drug Major Company Production Sites and Headquarters Table 35. Global Vaginosis Drug Company, Product Type & Application Table 36. Global Vaginosis Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Vaginosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Vaginosis Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Vaginosis Drug Sales by Region (2021-2026) & (k units) Table 41. Global Vaginosis Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global Vaginosis Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global Vaginosis Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Vaginosis Drug Sales by Region (2027-2032) & (k units) Table 46. Global Vaginosis Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global Vaginosis Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global Vaginosis Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Vaginosis Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Vaginosis Drug Sales by Application (2021-2026) & (k units) Table 52. Global Vaginosis Drug Sales Market Share in Volume by Application (2021-2026) Table 53. Global Vaginosis Drug Sales by Application (2021-2026) & (US$ Million) Table 54. Global Vaginosis Drug Sales Market Share in Value by Application (2021-2026) Table 55. Global Vaginosis Drug Price by Application (2021-2026) & (US$/unit) Table 56. Global Vaginosis Drug Sales by Application (2027-2032) & (k units) Table 57. Global Vaginosis Drug Sales Market Share in Volume by Application (2027-2032) Table 58. Global Vaginosis Drug Sales by Application (2027-2032) & (US$ Million) Table 59. Global Vaginosis Drug Sales Market Share in Value by Application (2027-2032) Table 60. Global Vaginosis Drug Price by Application (2027-2032) & (US$/unit) Table 61. North America Vaginosis Drug Sales by Application (2021-2026) & (k units) Table 62. North America Vaginosis Drug Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Vaginosis Drug Sales by Application (2021-2026) & (k units) Table 64. Europe Vaginosis Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Vaginosis Drug Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Vaginosis Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Vaginosis Drug Sales by Application (2021-2026) & (k units) Table 68. Latin America Vaginosis Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Vaginosis Drug Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Vaginosis Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Yunnan Baiyao Company Information Table 72. Yunnan Baiyao Business Overview Table 73. Yunnan Baiyao Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Yunnan Baiyao Vaginosis Drug Product Portfolio Table 75. Yunnan Baiyao Recent Development Table 76. Abbott Company Information Table 77. Abbott Business Overview Table 78. Abbott Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Abbott Vaginosis Drug Product Portfolio Table 80. Abbott Recent Development Table 81. Xiuzheng Company Information Table 82. Xiuzheng Business Overview Table 83. Xiuzheng Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Xiuzheng Vaginosis Drug Product Portfolio Table 85. Xiuzheng Recent Development Table 86. Teva Company Information Table 87. Teva Business Overview Table 88. Teva Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Teva Vaginosis Drug Product Portfolio Table 90. Teva Recent Development Table 91. Sanofi Company Information Table 92. Sanofi Business Overview Table 93. Sanofi Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Sanofi Vaginosis Drug Product Portfolio Table 95. Sanofi Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Pfizer Vaginosis Drug Product Portfolio Table 100. Pfizer Recent Development Table 101. Bayer Company Information Table 102. Bayer Business Overview Table 103. Bayer Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Bayer Vaginosis Drug Product Portfolio Table 105. Bayer Recent Development Table 106. West-Ward Company Information Table 107. West-Ward Business Overview Table 108. West-Ward Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. West-Ward Vaginosis Drug Product Portfolio Table 110. West-Ward Recent Development Table 111. Starpharma Company Information Table 112. Starpharma Business Overview Table 113. Starpharma Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Starpharma Vaginosis Drug Product Portfolio Table 115. Starpharma Recent Development Table 116. Piramal Company Information Table 117. Piramal Business Overview Table 118. Piramal Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Piramal Vaginosis Drug Product Portfolio Table 120. Piramal Recent Development Table 121. Perrigo Company Information Table 122. Perrigo Business Overview Table 123. Perrigo Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Perrigo Vaginosis Drug Product Portfolio Table 125. Perrigo Recent Development Table 126. Novel Company Information Table 127. Novel Business Overview Table 128. Novel Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Novel Vaginosis Drug Product Portfolio Table 130. Novel Recent Development Table 131. Mission Company Information Table 132. Mission Business Overview Table 133. Mission Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Mission Vaginosis Drug Product Portfolio Table 135. Mission Recent Development Table 136. HPGC Company Information Table 137. HPGC Business Overview Table 138. HPGC Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. HPGC Vaginosis Drug Product Portfolio Table 140. HPGC Recent Development Table 141. Galderma Company Information Table 142. Galderma Business Overview Table 143. Galderma Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Galderma Vaginosis Drug Product Portfolio Table 145. Galderma Recent Development Table 146. Edenvridge Company Information Table 147. Edenvridge Business Overview Table 148. Edenvridge Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Edenvridge Vaginosis Drug Product Portfolio Table 150. Edenvridge Recent Development Table 151. Alkem Company Information Table 152. Alkem Business Overview Table 153. Alkem Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. Alkem Vaginosis Drug Product Portfolio Table 155. Alkem Recent Development Table 156. North America Vaginosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 157. North America Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 158. North America Vaginosis Drug Sales Market Share by Country (2021-2026) Table 159. North America Vaginosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 160. North America Vaginosis Drug Sales Market Share Forecast by Country (2027-2032) Table 161. North America Vaginosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. North America Vaginosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 163. North America Vaginosis Drug Market Share by Country (2021-2026) Table 164. North America Vaginosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. North America Vaginosis Drug Market Share Forecast by Country (2027-2032) Table 166. Europe Vaginosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 167. Europe Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 168. Europe Vaginosis Drug Sales Market Share by Country (2021-2026) Table 169. Europe Vaginosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 170. Europe Vaginosis Drug Sales Market Share Forecast by Country (2027-2032) Table 171. Europe Vaginosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Europe Vaginosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 173. Europe Vaginosis Drug Market Share by Country (2021-2026) Table 174. Europe Vaginosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Europe Vaginosis Drug Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Vaginosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 178. Asia-Pacific Vaginosis Drug Sales Market Share by Country (2021-2026) Table 179. Asia-Pacific Vaginosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 180. Asia-Pacific Vaginosis Drug Sales Market Share Forecast by Country (2027-2032) Table 181. Asia-Pacific Vaginosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Asia-Pacific Vaginosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 183. Asia-Pacific Vaginosis Drug Market Share by Country (2021-2026) Table 184. Asia-Pacific Vaginosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Asia-Pacific Vaginosis Drug Market Share Forecast by Country (2027-2032) Table 186. Latin America Vaginosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 187. Latin America Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 188. Latin America Vaginosis Drug Sales Market Share by Country (2021-2026) Table 189. Latin America Vaginosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 190. Latin America Vaginosis Drug Sales Market Share Forecast by Country (2027-2032) Table 191. Latin America Vaginosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Latin America Vaginosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 193. Latin America Vaginosis Drug Market Share by Country (2021-2026) Table 194. Latin America Vaginosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Latin America Vaginosis Drug Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Vaginosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 198. Middle East and Africa Vaginosis Drug Sales Market Share by Country (2021-2026) Table 199. Middle East and Africa Vaginosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 200. Middle East and Africa Vaginosis Drug Sales Market Share Forecast by Country (2027-2032) Table 201. Middle East and Africa Vaginosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 202. Middle East and Africa Vaginosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 203. Middle East and Africa Vaginosis Drug Market Share by Country (2021-2026) Table 204. Middle East and Africa Vaginosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 205. Middle East and Africa Vaginosis Drug Market Share Forecast by Country (2027-2032) Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Vaginosis Drug Distributors List Table 209. Vaginosis Drug Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Vaginosis Drug Image Figure 2. Global Vaginosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaginosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaginosis Drug Sales (2021-2032) & (k units) Figure 5. Rx Image Figure 6. Global Rx Sales YoY Growth (2021-2032) & (k units) Figure 7. OTC Image Figure 8. Global OTC Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Vaginosis Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Vaginosis Drug Market Share by Type 2025 VS 2032 Figure 11. North America Vaginosis Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America Vaginosis Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe Vaginosis Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe Vaginosis Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Vaginosis Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Vaginosis Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America Vaginosis Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Vaginosis Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Vaginosis Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Vaginosis Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Vaginosis Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 25. Pharmacy Image Figure 26. Global Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Vaginosis Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Vaginosis Drug Market Share by Application 2025 VS 2032 Figure 31. North America Vaginosis Drug Sales Market Share in Volume by Application in 2025 Figure 32. North America Vaginosis Drug Sales Market Share in Value by Application in 2025 Figure 33. Europe Vaginosis Drug Sales Market Share in Volume by Application in 2025 Figure 34. Europe Vaginosis Drug Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Vaginosis Drug Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Vaginosis Drug Sales Market Share in Value by Application in 2025 Figure 37. Latin America Vaginosis Drug Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Vaginosis Drug Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Vaginosis Drug Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Vaginosis Drug Sales Market Share in Value by Application in 2025 Figure 41. North America Vaginosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Vaginosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Vaginosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Vaginosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Vaginosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Vaginosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Vaginosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Vaginosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Vaginosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Vaginosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Vaginosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Vaginosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Vaginosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Vaginosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Vaginosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Vaginosis Drug Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Vaginosis Drug Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Rx
  • OTC
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Yunnan Baiyao
  • Abbott
  • Xiuzheng
  • Teva
  • Sanofi
  • Pfizer
  • Bayer
  • West-Ward
  • Starpharma
  • Piramal
  • Perrigo
  • Novel
  • Mission
  • HPGC
  • Galderma
  • Edenvridge
  • Alkem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vaginosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vaginosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vaginosis Drug Market by Type
  6. 1.3.1 Rx
  7. 1.3.2 OTC
  8. 1.4 Global Vaginosis Drug Market Size by Type
  9. 1.4.1 Global Vaginosis Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Vaginosis Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Vaginosis Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Vaginosis Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Vaginosis Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Vaginosis Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Vaginosis Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Vaginosis Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vaginosis Drug Industry Trends
  2. 2.2 Vaginosis Drug Industry Drivers
  3. 2.3 Vaginosis Drug Industry Opportunities and Challenges
  4. 2.4 Vaginosis Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vaginosis Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Vaginosis Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Vaginosis Drug Price (2021-2026)
  4. 3.4 Global Vaginosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vaginosis Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Vaginosis Drug Company, Product Type & Application
  7. 3.7 Global Vaginosis Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vaginosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vaginosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vaginosis Drug Tier 1, Tier 2, and Tier 3
4 Vaginosis Drug Regional Status and Outlook
  1. 4.1 Global Vaginosis Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vaginosis Drug Historic Market Size by Region
  3. 4.2.1 Global Vaginosis Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vaginosis Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vaginosis Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vaginosis Drug Forecasted Market Size by Region
  7. 4.3.1 Global Vaginosis Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vaginosis Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vaginosis Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vaginosis Drug by Application
  1. 5.1 Vaginosis Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Vaginosis Drug Market Size by Application
  6. 5.2.1 Global Vaginosis Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Vaginosis Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Vaginosis Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Vaginosis Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Vaginosis Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Vaginosis Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Vaginosis Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Vaginosis Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Yunnan Baiyao
  2. 6.1.1 Yunnan Baiyao Company Information
  3. 6.1.2 Yunnan Baiyao Business Overview
  4. 6.1.3 Yunnan Baiyao Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Yunnan Baiyao Vaginosis Drug Product Portfolio
  6. 6.1.5 Yunnan Baiyao Recent Developments
  7. 6.2 Abbott
  8. 6.2.1 Abbott Company Information
  9. 6.2.2 Abbott Business Overview
  10. 6.2.3 Abbott Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Abbott Vaginosis Drug Product Portfolio
  12. 6.2.5 Abbott Recent Developments
  13. 6.3 Xiuzheng
  14. 6.3.1 Xiuzheng Company Information
  15. 6.3.2 Xiuzheng Business Overview
  16. 6.3.3 Xiuzheng Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Xiuzheng Vaginosis Drug Product Portfolio
  18. 6.3.5 Xiuzheng Recent Developments
  19. 6.4 Teva
  20. 6.4.1 Teva Company Information
  21. 6.4.2 Teva Business Overview
  22. 6.4.3 Teva Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Teva Vaginosis Drug Product Portfolio
  24. 6.4.5 Teva Recent Developments
  25. 6.5 Sanofi
  26. 6.5.1 Sanofi Company Information
  27. 6.5.2 Sanofi Business Overview
  28. 6.5.3 Sanofi Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Vaginosis Drug Product Portfolio
  30. 6.5.5 Sanofi Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Vaginosis Drug Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Bayer
  38. 6.7.1 Bayer Company Information
  39. 6.7.2 Bayer Business Overview
  40. 6.7.3 Bayer Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Bayer Vaginosis Drug Product Portfolio
  42. 6.7.5 Bayer Recent Developments
  43. 6.8 West-Ward
  44. 6.8.1 West-Ward Company Information
  45. 6.8.2 West-Ward Business Overview
  46. 6.8.3 West-Ward Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 West-Ward Vaginosis Drug Product Portfolio
  48. 6.8.5 West-Ward Recent Developments
  49. 6.9 Starpharma
  50. 6.9.1 Starpharma Company Information
  51. 6.9.2 Starpharma Business Overview
  52. 6.9.3 Starpharma Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Starpharma Vaginosis Drug Product Portfolio
  54. 6.9.5 Starpharma Recent Developments
  55. 6.10 Piramal
  56. 6.10.1 Piramal Company Information
  57. 6.10.2 Piramal Business Overview
  58. 6.10.3 Piramal Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Piramal Vaginosis Drug Product Portfolio
  60. 6.10.5 Piramal Recent Developments
  61. 6.11 Perrigo
  62. 6.11.1 Perrigo Company Information
  63. 6.11.2 Perrigo Business Overview
  64. 6.11.3 Perrigo Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Perrigo Vaginosis Drug Product Portfolio
  66. 6.11.5 Perrigo Recent Developments
  67. 6.12 Novel
  68. 6.12.1 Novel Company Information
  69. 6.12.2 Novel Business Overview
  70. 6.12.3 Novel Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Novel Vaginosis Drug Product Portfolio
  72. 6.12.5 Novel Recent Developments
  73. 6.13 Mission
  74. 6.13.1 Mission Company Information
  75. 6.13.2 Mission Business Overview
  76. 6.13.3 Mission Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Mission Vaginosis Drug Product Portfolio
  78. 6.13.5 Mission Recent Developments
  79. 6.14 HPGC
  80. 6.14.1 HPGC Company Information
  81. 6.14.2 HPGC Business Overview
  82. 6.14.3 HPGC Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 HPGC Vaginosis Drug Product Portfolio
  84. 6.14.5 HPGC Recent Developments
  85. 6.15 Galderma
  86. 6.15.1 Galderma Company Information
  87. 6.15.2 Galderma Business Overview
  88. 6.15.3 Galderma Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Galderma Vaginosis Drug Product Portfolio
  90. 6.15.5 Galderma Recent Developments
  91. 6.16 Edenvridge
  92. 6.16.1 Edenvridge Company Information
  93. 6.16.2 Edenvridge Business Overview
  94. 6.16.3 Edenvridge Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Edenvridge Vaginosis Drug Product Portfolio
  96. 6.16.5 Edenvridge Recent Developments
  97. 6.17 Alkem
  98. 6.17.1 Alkem Company Information
  99. 6.17.2 Alkem Business Overview
  100. 6.17.3 Alkem Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Alkem Vaginosis Drug Product Portfolio
  102. 6.17.5 Alkem Recent Developments
7 North America by Country
  1. 7.1 North America Vaginosis Drug Sales by Country
  2. 7.1.1 North America Vaginosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vaginosis Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Vaginosis Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vaginosis Drug Market Size by Country
  6. 7.2.1 North America Vaginosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vaginosis Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Vaginosis Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vaginosis Drug Sales by Country
  2. 8.1.1 Europe Vaginosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vaginosis Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Vaginosis Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vaginosis Drug Market Size by Country
  6. 8.2.1 Europe Vaginosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vaginosis Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vaginosis Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vaginosis Drug Sales by Country
  2. 9.1.1 Asia-Pacific Vaginosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vaginosis Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vaginosis Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vaginosis Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Vaginosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vaginosis Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vaginosis Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vaginosis Drug Sales by Country
  2. 10.1.1 South America Vaginosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vaginosis Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Vaginosis Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vaginosis Drug Market Size by Country
  6. 10.2.1 South America Vaginosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vaginosis Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Vaginosis Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vaginosis Drug Sales by Country
  2. 11.1.1 Middle East and Africa Vaginosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vaginosis Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vaginosis Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vaginosis Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Vaginosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vaginosis Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vaginosis Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vaginosis Drug Value Chain Analysis
  2. 12.1.1 Vaginosis Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vaginosis Drug Production Mode & Process
  7. 12.2 Vaginosis Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vaginosis Drug Distributors
  10. 12.2.3 Vaginosis Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst